Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
- Sysco calls on Teamsters to end LA strike after economic deal reached
Edwards Lifesciences (EW) PT Raised to $136 at Jefferies Following Investor Day
December 8, 2017 6:50 AM ESTJefferies raised its price target on Edwards Lifesciences (NYSE: EW) to $136.00 (from $132.00) while maintaining a Buy rating.
Analyst Raj Denhoy highlighted three conclusions from EWs annual investor briefing:
1. With efforts to tap less sick, undiagnosed, and untreated populations along with continued... More
Edwards Lifesciences (EW) PT Raised to $135 at Cowen
December 8, 2017 6:40 AM ESTCowen raised its price target on Edwards Lifesciences (NYSE: EW) to $135.00 (from $130.00) while maintaining a Outperform rating.
Analyst Joshua Jennings said EW's 2018 targets are likely conservative and were well received. Jennings said the update to the WW TAVR franchise leaves room for 2018 upside and... More



